Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: To describe outcomes with the use of neoadjuvant pelvic chemoradiation followed by prostate interstitial brachytherapy for the treatment of synchronous prostate and rectal cancers.
Methods And Materials: An Internal Review Board approved retrospective review was undertaken of 4 patients with synchronous prostate and rectal cancer treated between 2006 and 2008. Patients underwent pelvic chemoradiation followed by prostate brachytherapy, then low anterior resection of the rectum with diverting loop ileostomy and adjuvant chemotherapy. Follow-up evaluation included imaging and laboratory analysis of cancer markers in addition to routine interval history and physical examination.
Results: At 38-62 months postdiagnosis (24-53 months post-treatment), 6 of 8 cancers remained without evidence of relapse. One patient had rising carcinoembryonic antigen levels but no clinically evident rectal cancer relapse; another developed bony metastasis of his high-risk prostate cancer. Three patients experienced grade 1-2 treatment-related toxicity; one patient had grade 3 gastrointestinal toxicity from radiation and surgery, which precluded his receiving adjuvant chemotherapy and ileostomy reversal.
Conclusions: Chemoradiation followed by prostate brachytherapy, surgery, and adjuvant chemotherapy may be utilized to manage patients with synchronous prostate and rectal cancers.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.prro.2011.11.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Interconnected study of molecular pathways: miR-137 as a central element at the intersection of lipid metabolism and prostate carcinogenesis.
Einstein (Sao Paulo)
September 2025
Instituto D'Or de Pesquisa e Educação, São Paulo, SP, Brazil.
Objective: To evaluate the roles of miR-137 and its target genes in lipid metabolism and prostate tumorigenesis.
Methods: We used a series of bioinformatic approaches to establish the relationship between miR-137 and its target genes. We mapped the metabolic pathways of interest in the Reactome database and identified the central target genes of miR-137 in this pathway using four platforms: Reactome, miRDB, miRmap, and TargetScan.
Castleman disease with synchronous primary rectal and prostate cancers: a case report of successful multimodal treatment and 2-year recurrence-free survival.
Front Oncol
August 2025
Department of Radiation Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, China.
Background: Castleman disease (CD) is a rare lymphoproliferative disorder associated with immune dysregulation that may increase the risk of malignancy. Synchronous multiple primary cancers are uncommon, and their etiology remains largely unclear. The coexistence of CD with synchronous multiple primary malignancies is exceptionally rare; therefore, the underlying mechanisms and optimal treatment strategies deserve further investigation.
View Article and Find Full Text PDFAnalysis of Metastases and Second Primary Malignancy Development in Patients with Invasive Transitional Cell Carcinoma of the Bladder.
Cancers (Basel)
August 2025
The Legacy Heritage Cancer Center, Dr. Larry Norton Institute, Soroka Medical Center, Beer-Sheva 84105, Israel.
Invasive BC patients are at risk of loco-regional recurrence, distant MTS, and the development of second primary tumors. SPMs comprise the sixth most common group of malignancies. The records of 125 consecutive patients with primary invasive TCC of the bladder seen in the Oncology Department of Soroka University Medical Center were reviewed between January 2016 and December 2023.
View Article and Find Full Text PDFThe Influence of the Introduction of PSMA-PET/CT in Danish Men Diagnosed with Prostate Cancer.
Clin Genitourin Cancer
July 2025
Copenhagen Prostate Cancer Center, Department of Urology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Background: Conventional imaging in patients with newly diagnosed prostate cancer is gradually being replaced with PSMA-PET/CT. However, the possible impact of newer imaging modalities on stage migration is poorly understood. We have studied the effects of introducing PSMA-PET/CT on the incidence of newly diagnosed hormone-sensitive prostate cancer.
View Article and Find Full Text PDFTriplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach.
Oncol Rev
July 2025
Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
This article aims to critically evaluate the evidence for triplet therapy consisting of androgen deprivation therapy (ADT), docetaxel and a second-generation androgen receptor pathway inhibitor ([ARPI]; abiraterone, enzalutamide, darolutamide or apalutamide) in patients with metastatic hormone-sensitive prostate cancer (mHSPC), and what this evidence reveals regarding the use of these treatments in clinical practice. A search of PubMed, Medline, Embase, Cochrane, Scopus and Web of Science was conducted in April 2024 to identify relevant prospective and retrospective observational trials, randomized controlled trials (RCTs) and meta-analyses. The search identified 52 relevant articles: six full articles and 31 abstracts based on three RCTs, one observational study and 14 meta-analyses.
View Article and Find Full Text PDF